3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Rectal Neoplasms
4
Nasopharyngeal Carcinoma
3
Esophageal Neoplasms
3
Colorectal Neoplasms
3
Barrett Esophagus
2
Urogenital Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Recurrence
1
Pathologic Complete Response
1
Paranasal Sinus Neoplasms
1
Ovarian Neoplasms
1
Nasopharyngeal Neoplasms
1
Lung Neoplasms
1
Locally Advanced Pancreatic Cancer
1
Jaw Cysts
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Colitis
1
Carcinoma, Non-Small-Cell Lung
1
Bacteremia
1
Interventions
Carboplatin
4
pertuzumab
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Paclitaxel
2
Oxaliplatin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
talazoparib
1
sarilumab
1
relugolix
1
regorafenib
1
pexidartinib
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
nimotuzumab
1
neratinib
1
ganitumab
1
enzalutamide
1
dostarlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Pathologic Complete Response
×
Endoscopy
×
Clear all
NCT03125343
2023-11-07
WoW
Sahlgrenska University Hospital
Phase NA
Recruiting
400 enrolled